Anti-SARS-CoV-2 Monoclonal Antibodies Studied in Patients with Lymphoma, COVID-19
By Cecilia Brown, Giovanni Manfredi Assanto - Last Updated: January 11, 2023Giovanni Manfredi Assanto, a doctoral candidate at Sapienza University of Rome, discusses research on the impact of anti-SARS-CoV-2 monoclonal antibodies in patients with lymphoma and COVID-19. The research was presented at the 2022 Annual American Society of Hematology Meeting.
Advertisement
Post Tags:Lymphoma ASH 22
Advertisement
Related Posts
New data on immune thrombocytopenia were most prominent but Meeting coverage ranged over several forms of the disease.
Andrew Kuykendall, MD, presented on the status of myelofibrosis treatment in the era of 4 approved JAK inhibitors.
The CARTITUDE-4, KarMMa-3, and DREAMM-7 trials are paving the way for immunotherapy in multiple myeloma.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.